Ethanolamine Oleate API Manufacturers

compare suppliers & get competitive offers



Selected filters:

Production region




To view suppliers for this material, you need to be logged in first.






This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.



Looking for Ethanolamine Oleate API 2272-11-9?

Here you will find a list of producers, manufacturers and distributors of Ethanolamine Oleate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Ethanolamine Oleate 
Ethamolin , Ethanolamine oleate , Monoethanolamine oleate , Oldamin  
Cas Number:
DrugBank number:
Unique Ingredient Identifier:

About Ethanolamine Oleate

Do you want to know more about Ethanolamine oleate? You can find a small explanation about it here. Ethanolamine oleate is a mild sclerosing agent. It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.

You can ask the supplier for more technical information about the product.

Ethanolamine Oleate is a type of Sclerosing agents

Sclerosing agents are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) used in various medical procedures. These agents are specifically formulated to induce sclerosis, a controlled and localized inflammatory response that leads to the formation of scar tissue. The primary purpose of sclerosing agents is to treat a wide range of medical conditions, including vascular malformations, varicose veins, hemorrhoids, and certain types of cysts.

Sclerosing agents work by causing irritation and inflammation at the target site, which triggers a series of biochemical reactions resulting in the formation of fibrous tissue. This fibrosis helps to close or shrink the affected blood vessels or abnormal growths, effectively addressing the underlying condition.

One commonly used sclerosing agent is polidocanol, a non-ionic detergent that acts by disrupting the endothelial lining of blood vessels, leading to thrombus formation and subsequent fibrosis. Another widely employed agent is sodium tetradecyl sulfate, which shares a similar mechanism of action. These agents are typically administered through injection directly into the affected area under the supervision of a medical professional.

The choice of sclerosing agent depends on factors such as the specific medical condition being treated, the size and location of the affected area, and the patient's overall health. Prior to administration, thorough evaluation and diagnosis by a healthcare provider are necessary to determine the appropriate sclerosing agent and dosage for optimal outcomes.

In conclusion, sclerosing agents play a crucial role in the treatment of various medical conditions by inducing controlled inflammation and scar tissue formation. With their targeted approach and effectiveness, these pharmaceutical APIs offer patients a promising therapeutic option to manage their specific ailments.

Ethanolamine Oleate (Sclerosing agents), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.